Deafness: Clinical Trials

7 trials for Deafness, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed. 7 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 17Completed 7
Phase 25Completed 5

Follow Deafness: new trials by email Literature Review of Deafness trials Research Report on Deafness

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss
PIPE-505, Placebo - Sensorineural Hearing Loss
Phase 1 / Phase 2CompletedContineum Therapeutics282020-10-152025-04-01
Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome
NPI-001, Placebo - Usher Syndromes
Phase 1 / Phase 2CompletedNacuity Pharmaceuticals, Inc.492020-09-032026-07-01
Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene
QR-421a, Sham-procedure (dose cohort 1&2 only) - Retinitis Pigmentosa, Usher Syndrome Type 2
Phase 1 / Phase 2CompletedProQR Therapeutics202019-03-062022-04-20
A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome
dantrolene sodium - Wolfram Syndrome, Diabetes Mellitus
Phase 1 / Phase 2CompletedWashington University School of Medicine212017-01-012024-03-13
A Safety Study of the Auditory Brainstem Implant for Pediatric Profoundly Deaf Patients
Auditory Brainstem Implant - Profound Bilateral Deafness Due to, Bilateral Cochlear Aplasia
Phase 1CompletedLaurie Eisenberg102014-03-012025-09-15
Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss
Ancrod, Saline solution - Hearing Loss, Deafness
Phase 1 / Phase 2CompletedNordmark Arzneimittel GmbH & Co. KG312013-05-012018-12-21
Outcomes In Children With Developmental Delay And Deafness
cochlear implantation, hearing aids - Deafness, Hearing Loss
Phase 1CompletedStanford University3032009-09-012016-11-15

Narrower conditions

Hearing Loss (3)  ·  Hearing Loss, Sensorineural (2)  ·  Usher Syndromes (2)  ·  Ataxia (1)  ·  Diabetes Mellitus (1)  ·  Ear Diseases (1)  ·  Eye Abnormalities (1)  ·  Eye Diseases (1)  ·  Eye Diseases, Hereditary (1)  ·  Hearing Disorders (1)  ·  Hearing Loss, Hidden (1)  ·  Intellectual Disability (1)  ·  Learning Disabilities (1)  ·  Optic Atrophy (1)

Broader conditions

Nervous System Diseases (7)  ·  Neurologic Manifestations (7)  ·  Otorhinolaryngologic Diseases (7)  ·  Pathological Conditions, Signs and Symptoms (7)  ·  Sensation Disorders (7)  ·  Signs and Symptoms (7)  ·  Ear Diseases (6)  ·  Hearing Disorders (6)  ·  Hearing Loss (4)  ·  Abnormalities, Multiple (3)  ·  Blindness (3)  ·  Congenital Abnormalities (3)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3)  ·  Deaf-Blind Disorders (3)

Interventions

Ancrod (1)  ·  Auditory Brain Stem Implants (1)  ·  Cochlear Implantation (1)  ·  Dantrolene (1)  ·  Hearing Aids (1)  ·  Intravitreal Injections (1)  ·  Saline Solution (1)

Sponsors

Contineum Therapeutics (1)  ·  Laurie Eisenberg (1)  ·  Nacuity Pharmaceuticals, Inc. (1)  ·  Nordmark Arzneimittel GmbH & Co. KG (1)  ·  ProQR Therapeutics (1)  ·  Stanford University (1)  ·  Washington University School of Medicine (1)

Countries

United States (5)  ·  Australia (1)  ·  Canada (1)  ·  Czechia (1)  ·  France (1)  ·  Germany (1)

Top investigators

Eric Wilkinson, MD (1)  ·  Fumihiko Urano, MD (1)  ·  John Oghalai (1)  ·  Laurie S. Eisenberg, PhD (1)  ·  Lee Anderson, MD (1)  ·  Martin Canis, MD PhD (1)  ·  Stephen Huhn, MD (1)

Results publications

PMID 26366332, PMID 27898605, PMID 29714549, PMID 29718280, PMID 31215818, PMID 34185708, PMID 35607935, PMID 37418643

NIH funding

2018 (1), R01DC010075 (1), R21DK113487 (1)